论文部分内容阅读
美国西尔药厂和默克公司目前正致力于将各自的ＣＯＸ－２抑制剂ｃｅｌｅｃｏｘｉｂ和ｒｏｆｅｃｏｘｉｂ用于两种新的适应证的治疗：结肠癌和阿尔茨海默病。西尔药厂与辉瑞公司联合进行的ｃｅｌｅｃｏｘｉｂ治疗结肠癌的研究已进入Ⅲ期临床，ｃｅｌｅｃｏｘｉｂ在治疗家族性腺
USSil Pharmaceuticals and Merck are currently working on the use of their respective COX-2 inhibitors celecoxib and rofecoxib for the treatment of two new indications: colon cancer and Alzheimer’s disease. The study of celecoxib for the treatment of colon cancer has been carried out in Phase III clinically in combination with Pfizer and Pfizer, and celecoxib is used to treat familial gonads.